Elsevier

Journal of Hepatology

Volume 27, Issue 4, October 1997, Pages 677-687
Journal of Hepatology

Basic fibroblast growth factor regulates proliferation and motility of human hepatoma cells by an autocrine mechanism

https://doi.org/10.1016/S0168-8278(97)80085-2Get rights and content

Abstract

Background/Aims: Basic fibroblast growth factor has mitogenic and angiogenic properties. In this study, we aimed to evaluate the role of fibroblast growth factor in the development and progression of human hepatocellular carcinoma.

Methods: The expression of basic fibroblast growth factor, fibroblast growth factor receptor-1, and a receptor isoform was investigated by in situ hybridization, immunohistochemistry, reverse transcription-polymerase chain reaction, Western blot analysis and confocal laser-scanning microscopy. The influence of exogenous basic fibroblast growth factor on DNA synthesis and motility of human hepatoma cells were also evaluated.

Results: Basic fibroblast growth factor and fibroblast growth factor receptor-1 messenger RNAs were present mainly in tumor cells and less so in hepatocytes from noncancerous liver tissue. Immunoreactive products of basic fibroblast growth factor and fibroblast growth factor receptor-1 were observed in tumor cells. The isoform IIIc was expressed in hepatocellular carcinoma tissue and hepatoma cell lines. Exogenous basic fibroblast growth factor stimulated DNA synthesis and motility of hepatoma cells. The effect was more marked in poorly-differentiated hepatoma cells than in well-differentiated hepatoma cells. Fibroblast growth factor-1 expression on hepatoma cells was also more marked in poorly-differentiated hepatoma cells than in well-differentiated hepatoma cells. The stimulated motility on basic fibroblast growth factor was suppressed by an anti-fibroblast growth factor receptor-1 antibody.

Conclusions: Basic fibroblast growth factor may play an important role in the development and progression of hepatocellular carcinoma via an autocrine mechanism involving fibroblast growth factor and its receptor.

References (47)

  • C Liu et al.

    Transforming growth factors produced by normal and neoplastically transformed rat liver epithelial cells in culture

    Cancer Res

    (1988)
  • T Fukusato et al.

    Immunohistochemical and ultrastructural localization of epidermal growth factor receptor in human liver and hepatocellular carcinoma tissues

    Acta Pathol Jpn

    (1990)
  • LW Lee et al.

    Clonal cosegregation of tumorigenicity with overexpression of c-myc and transforming growth factor α genes in chemically transformed rat liver epithelial cells

    Cancer Res

    (1991)
  • D Rifkin et al.

    Recent developments in the cell biology of basic fibroblast growth factor

    J Cell Biol

    (1989)
  • WH Burgess et al.

    The heparin-binding (fibroblast) growth factor family of proteins

    Annu Rev Biochem

    (1989)
  • G Neufeld et al.

    Expression of human basic fibroblast growth factor cDNA in baby hamster kidney-derived cells results in autonomous cell growth

    J Cell Biol

    (1988)
  • S Rogelj et al.

    Basic fibroblast growth factor fused to a signal peptide transforms cells

    Nature

    (1988)
  • R Sasada et al.

    Transformation of mouse BALB/c 3T3 cells with human basic fibroblast growth factor cDNA

    Mol Cell Biol

    (1988)
  • YA Luqmani et al.

    Expression of basic fibroblast human breast, and comparison with other normal tissues

    Br J Cancer

    (1992)
  • F Yamaguchi et al.

    Differential expression of two fibroblast growth factor-receptor genes is associated with malignant progression in human astrocytomas

    Proc Natl Acad Sci USA

    (1994)
  • Y Yamanaka et al.

    Overexpression of acidic and basic fibroblast growth factors in human pancreatic cancer correlates with advanced tumor stage

    Cancer Res

    (1993)
  • MS Kobrin et al.

    Aberrant expression of type 1 fibroblast growth factor receptor in human pancreatic adenocarcinomas

    Cancer Res

    (1993)
  • DE Johnson et al.

    Structural and functional diversity in the FGF receptor multigene family

    Adv Cancer Res

    (1993)
  • Cited by (68)

    • NCAM- and FGF-2-mediated FGFR1 signaling in the tumor microenvironment of esophageal cancer regulates the survival and migration of tumor-associated macrophages and cancer cells

      2016, Cancer Letters
      Citation Excerpt :

      FGF-2 promotes the chemotaxis and proliferation of endothelial cells through Erk1/2 signaling, resulting in wound repair [48,49]. The autocrine, paracrine and intracrine growth promotion of FGF-2/FGFR1 signaling has been confirmed in various tumors [50–53]. In macrophages, the induction of vasculogenic mimicry formation in multiple myeloma is involved in the promotion of macrophage chemotaxis through an FGF-2/FGFR1 paracrine mechanism [54].

    • Therapeutic uses of FGFs

      2016, Seminars in Cell and Developmental Biology
      Citation Excerpt :

      In vitro studies demonstrate an upregulation of FGF5 in the majority of renal cell, prostate, and breast carcinoma cell lines [35]. The upregulation of FGF8, 17 and 18 occur in HCC [36,37]. In several preclinical models, FGF4, 5, 8 and 18 overexpression appear to promote tumor formation via modulating blood vessel growth by the cross-talk between FGFs, vascular endothelial growth factors (VEGFs), and inflammatory cytokines/chemokines [38].

    • The prognostic significance of vasohibin 1-associated angiogenesis in patients with hepatocellular carcinoma

      2014, Human Pathology
      Citation Excerpt :

      FGF-2 is also reported to have a direct effect on the proliferation activity of ECs, which was determined by double immunostaining of CD34 and proliferating cell nuclear antigen [28]. In addition, FGF-2 stimulates DNA synthesis and cell motility in tumor cells of HCC in an autocrine manner [29]. These results suggest that FGF-2 secretion may play potent roles in tumor-associated angiogenesis and progression in HCC.

    • The evolving landscape of therapeutic drug development for hepatocellular carcinoma

      2013, Contemporary Clinical Trials
      Citation Excerpt :

      FGF is highly expressed in HCC. It promotes cell proliferation via an autocrine mechanism [39,40] and has been shown to augment the angiogenic effect of VEGF [40]. Although originally identified as a Raf kinase inhibitor, sorafenib's activity in HCC is believed to be due to inhibition of VEGFR [41].

    View all citing articles on Scopus
    View full text